Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patientsBusiness Wire • 08/24/21
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patientsGlobeNewsWire • 08/23/21
Is the Options Market Predicting a Spike in Cara Therapeutics (CARA) Stock?Zacks Investment Research • 08/11/21
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Cara Therapeutics (CARA) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/09/21
Cara Therapeutics (CARA) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/02/21
Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021GlobeNewsWire • 08/02/21
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/11/21
Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021GlobeNewsWire • 05/03/21